As of close of business last night, Janux Therapeutics Inc’s stock clocked out at $50.55, down -2.53% from its previous closing price of $51.86. On the day, 536310 shares were traded.
Ratios:
To gain a deeper understanding of JANX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 26.80 and its Current Ratio is at 26.80. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on March 21, 2024, initiated with a Buy rating and assigned the stock a target price of $62.
On March 20, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $100.
On April 06, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $24.Wedbush initiated its Outperform rating on April 06, 2023, with a $24 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 13 ’23 when Avalon Ventures XI, L.P. bought 849,854 shares for $5.87 per share. The transaction valued at 4,988,643 led to the insider holds 849,854 shares of the business.
Reardon Tighe bought 849,854 shares of JANX for $4,988,643 on Nov 13 ’23. The Acting Chief Financial Officer now owns 849,854 shares after completing the transaction at $5.87 per share. On Nov 13 ’23, another insider, Lichter Jay, who serves as the Director of the company, bought 849,854 shares for $5.87 each. As a result, the insider paid 4,988,643 and bolstered with 849,854 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 323.19 while its Price-to-Book (P/B) ratio in mrq is 6.79.
Stock Price History:
Over the past 52 weeks, JANX has reached a high of $58.69, while it has fallen to a 52-week low of $5.65.
Shares Statistics:
A total of 46.25M shares are outstanding, with a floating share count of 34.43M. Insiders hold about 33.35% of the company’s shares, while institutions hold 57.77% stake in the company.
Earnings Estimates
As of right now, Jaguar Health, Inc. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $50.55, with high estimates of $3.16 and low estimates of $3.82.
Analysts are recommending an EPS of between $Healthcare and $Industrials for the fiscal current year, implying an average EPS of $Healthcare.
